Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease

Jeffrey R. Marks, Karen Anderson, Paul Engstrom, Andrew K. Godwin, Laura J. Esserman, Gary Longton, Edwin S. Iversen, Anu Mathew, Christos Patriotis, Margaret S. Pepe

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Background: Many circulating biomarkers have been reported for the diagnosis of breast cancer, but few, if any, have undergone rigorous credentialing using prospective cohorts and blinded evaluation.

    Methods: The NCI Early Detection Research Network (EDRN) has created a prospective, multicenter collection of plasma and serum samples from 832 subjects designed to evaluate circulating biomarkers for the detection and diagnosis of breast cancer. These samples are available to investigators who wish to evaluate their biomarkers using a set of blinded samples. The breast cancer reference set is composed of blood samples collected using a standard operating procedure at four U.S. medical centers from 2008 to 2010 from women undergoing either tissue diagnosis for breast cancer or routine screeningmammography. The reference set contains samples from women with incident invasive cancer (n=190), carcinoma in situ (n=55), benign pathology with atypia (n=63), benign disease withno atypia (n=231), andwomenwith no evidence of breast disease by screening mammography (BIRADS 1 or 2, n=276). Using a subset of plasma samples (n=505) from the reference set, we analyzed 90 proteins by multiplexed immunoassays for their potential utility as diagnostic markers.

    Results: We found that none of these markers is useful for distinguishing cancer from benign controls. However, elevated CA-125 does appear to be a candidate marker for estrogen receptor-negative cancers.

    Conclusions: Markers that can distinguish benign breast conditions from invasive cancer have not yet been found.

    Impact: Availability of prospectively collected samples should improve future validation efforts.

    Original languageEnglish (US)
    Pages (from-to)435-441
    Number of pages7
    JournalCancer Epidemiology Biomarkers and Prevention
    Volume24
    Issue number2
    DOIs
    StatePublished - Feb 1 2015

    Fingerprint

    Breast Neoplasms
    Biomarkers
    Research
    Neoplasms
    Credentialing
    Breast Diseases
    Carcinoma in Situ
    Mammography
    Immunoassay
    Estrogen Receptors
    Breast
    Research Personnel
    Pathology
    Serum
    Proteins

    ASJC Scopus subject areas

    • Epidemiology
    • Oncology

    Cite this

    Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. / Marks, Jeffrey R.; Anderson, Karen; Engstrom, Paul; Godwin, Andrew K.; Esserman, Laura J.; Longton, Gary; Iversen, Edwin S.; Mathew, Anu; Patriotis, Christos; Pepe, Margaret S.

    In: Cancer Epidemiology Biomarkers and Prevention, Vol. 24, No. 2, 01.02.2015, p. 435-441.

    Research output: Contribution to journalArticle

    Marks, JR, Anderson, K, Engstrom, P, Godwin, AK, Esserman, LJ, Longton, G, Iversen, ES, Mathew, A, Patriotis, C & Pepe, MS 2015, 'Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease' Cancer Epidemiology Biomarkers and Prevention, vol. 24, no. 2, pp. 435-441. https://doi.org/10.1158/1055-9965.EPI-14-1178
    Marks, Jeffrey R. ; Anderson, Karen ; Engstrom, Paul ; Godwin, Andrew K. ; Esserman, Laura J. ; Longton, Gary ; Iversen, Edwin S. ; Mathew, Anu ; Patriotis, Christos ; Pepe, Margaret S. / Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. In: Cancer Epidemiology Biomarkers and Prevention. 2015 ; Vol. 24, No. 2. pp. 435-441.
    @article{c8f3b4831bbb4b4797382becb735b940,
    title = "Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease",
    abstract = "Background: Many circulating biomarkers have been reported for the diagnosis of breast cancer, but few, if any, have undergone rigorous credentialing using prospective cohorts and blinded evaluation.Methods: The NCI Early Detection Research Network (EDRN) has created a prospective, multicenter collection of plasma and serum samples from 832 subjects designed to evaluate circulating biomarkers for the detection and diagnosis of breast cancer. These samples are available to investigators who wish to evaluate their biomarkers using a set of blinded samples. The breast cancer reference set is composed of blood samples collected using a standard operating procedure at four U.S. medical centers from 2008 to 2010 from women undergoing either tissue diagnosis for breast cancer or routine screeningmammography. The reference set contains samples from women with incident invasive cancer (n=190), carcinoma in situ (n=55), benign pathology with atypia (n=63), benign disease withno atypia (n=231), andwomenwith no evidence of breast disease by screening mammography (BIRADS 1 or 2, n=276). Using a subset of plasma samples (n=505) from the reference set, we analyzed 90 proteins by multiplexed immunoassays for their potential utility as diagnostic markers.Results: We found that none of these markers is useful for distinguishing cancer from benign controls. However, elevated CA-125 does appear to be a candidate marker for estrogen receptor-negative cancers.Conclusions: Markers that can distinguish benign breast conditions from invasive cancer have not yet been found.Impact: Availability of prospectively collected samples should improve future validation efforts.",
    author = "Marks, {Jeffrey R.} and Karen Anderson and Paul Engstrom and Godwin, {Andrew K.} and Esserman, {Laura J.} and Gary Longton and Iversen, {Edwin S.} and Anu Mathew and Christos Patriotis and Pepe, {Margaret S.}",
    year = "2015",
    month = "2",
    day = "1",
    doi = "10.1158/1055-9965.EPI-14-1178",
    language = "English (US)",
    volume = "24",
    pages = "435--441",
    journal = "Cancer Epidemiology Biomarkers and Prevention",
    issn = "1055-9965",
    publisher = "American Association for Cancer Research Inc.",
    number = "2",

    }

    TY - JOUR

    T1 - Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease

    AU - Marks, Jeffrey R.

    AU - Anderson, Karen

    AU - Engstrom, Paul

    AU - Godwin, Andrew K.

    AU - Esserman, Laura J.

    AU - Longton, Gary

    AU - Iversen, Edwin S.

    AU - Mathew, Anu

    AU - Patriotis, Christos

    AU - Pepe, Margaret S.

    PY - 2015/2/1

    Y1 - 2015/2/1

    N2 - Background: Many circulating biomarkers have been reported for the diagnosis of breast cancer, but few, if any, have undergone rigorous credentialing using prospective cohorts and blinded evaluation.Methods: The NCI Early Detection Research Network (EDRN) has created a prospective, multicenter collection of plasma and serum samples from 832 subjects designed to evaluate circulating biomarkers for the detection and diagnosis of breast cancer. These samples are available to investigators who wish to evaluate their biomarkers using a set of blinded samples. The breast cancer reference set is composed of blood samples collected using a standard operating procedure at four U.S. medical centers from 2008 to 2010 from women undergoing either tissue diagnosis for breast cancer or routine screeningmammography. The reference set contains samples from women with incident invasive cancer (n=190), carcinoma in situ (n=55), benign pathology with atypia (n=63), benign disease withno atypia (n=231), andwomenwith no evidence of breast disease by screening mammography (BIRADS 1 or 2, n=276). Using a subset of plasma samples (n=505) from the reference set, we analyzed 90 proteins by multiplexed immunoassays for their potential utility as diagnostic markers.Results: We found that none of these markers is useful for distinguishing cancer from benign controls. However, elevated CA-125 does appear to be a candidate marker for estrogen receptor-negative cancers.Conclusions: Markers that can distinguish benign breast conditions from invasive cancer have not yet been found.Impact: Availability of prospectively collected samples should improve future validation efforts.

    AB - Background: Many circulating biomarkers have been reported for the diagnosis of breast cancer, but few, if any, have undergone rigorous credentialing using prospective cohorts and blinded evaluation.Methods: The NCI Early Detection Research Network (EDRN) has created a prospective, multicenter collection of plasma and serum samples from 832 subjects designed to evaluate circulating biomarkers for the detection and diagnosis of breast cancer. These samples are available to investigators who wish to evaluate their biomarkers using a set of blinded samples. The breast cancer reference set is composed of blood samples collected using a standard operating procedure at four U.S. medical centers from 2008 to 2010 from women undergoing either tissue diagnosis for breast cancer or routine screeningmammography. The reference set contains samples from women with incident invasive cancer (n=190), carcinoma in situ (n=55), benign pathology with atypia (n=63), benign disease withno atypia (n=231), andwomenwith no evidence of breast disease by screening mammography (BIRADS 1 or 2, n=276). Using a subset of plasma samples (n=505) from the reference set, we analyzed 90 proteins by multiplexed immunoassays for their potential utility as diagnostic markers.Results: We found that none of these markers is useful for distinguishing cancer from benign controls. However, elevated CA-125 does appear to be a candidate marker for estrogen receptor-negative cancers.Conclusions: Markers that can distinguish benign breast conditions from invasive cancer have not yet been found.Impact: Availability of prospectively collected samples should improve future validation efforts.

    UR - http://www.scopus.com/inward/record.url?scp=84922724941&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84922724941&partnerID=8YFLogxK

    U2 - 10.1158/1055-9965.EPI-14-1178

    DO - 10.1158/1055-9965.EPI-14-1178

    M3 - Article

    VL - 24

    SP - 435

    EP - 441

    JO - Cancer Epidemiology Biomarkers and Prevention

    JF - Cancer Epidemiology Biomarkers and Prevention

    SN - 1055-9965

    IS - 2

    ER -